May 26, 2023: 

Big Ten CRC lung cancer study to be presented at American Society of Clinical Oncology (ASCO) 2023 Annual Meeting in Chicago. Cynthia Wei, MD of the Indiana University School of Medicine will present on the Big Ten CRC study titled, “Phase II Study of Consolidation Immunotherapy with Nivolumab and Ipilimumab or Nivolumab alone following Concurrent Chemoradiotherapy for Unresectable Stage IIIA/IIIB Non-small Cell Lung Cancer (NSCLC).” Read More

May 1, 2023: 

Big Ten Cancer Research Consortium (Big Ten CRC) will have an exhibitors booth at the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting. Visit Booth #28115 to talk with our highly qualified staff about managing oncology/hematology multi-center clinical trials. Read More

March 27, 2023: 

Results from a Big Ten CRC bladder cancer study of concurrent durvalumab and radiation therapy (DUART) followed by adjuvant durvalumab in patients with localized urothelial cancer of bladder were published in the Journal for ImmunoTherapy of Cancer. Sponsor-investigator Monika Joshi, MD, of Penn State Cancer Institute led this single-arm, multi-institutional phase II study.
Read More

February 15, 2023:

The University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center (UMGCCC) has a long and distinguished history of advancing the field of cancer care. Among the Center’s significant advances are pioneering work into aromatase inhibitors and the development of GammaPod radiation therapy, both for breast cancer.

February 15, 2023:

Investigators of two Big Ten CRC studies presented their findings during the American Society of Clinical Oncology Genitourinary (GU) Cancers Symposium on February 16-18, 2023, in San Francisco, CA. Sara E. Fenton, MD, PhD of Northwestern University will present a Big Ten Cancer Research Consortium prostate cancer study and Yousef Zakharia of the Iowa Holden Comprehensive Cancer Center will present on a renal cell carcinoma study. 

Read More

November 12, 2022:

Cheryl L. Knott, PhD, is a Professor in the Department of Behavioral and Community Health, as well as Co-Leader of the Population Science Program and Associate Director of Community Outreach and Engagement at the University of Maryland Greenebaum Comprehensive Cancer Center. She is also Editor-in-Chief of the peer-reviewed journal, Translational Behavioral Medicine.

December 8, 2022:

Ali Ajrouch, MD, is a thoracic oncology post doctoral fellow at the Indiana University Melvin and Bren Simon Comprehensive Cancer Center.

Dr. Ajrouch’s current research focuses on improving outcomes in lung cancer patients. This includes improving health disparity by increasing access to lung cancer screening and early detection, identifying factors delaying patient care, incorporating novel technologies to personalize treatments and understanding treatment side effects.

November 29, 2022:

By Nasser Hanna, M.D.

Since it’s Lung Cancer Awareness Month, I’d like to tell you about an initiative that we started at the Indiana University Melvin and Bren Simon Comprehensive Cancer. It’s called End Lung Cancer Now, and we recently wrapped up what we called a “gathering.” The event included guest speakers from Roswell Park Comprehensive Cancer Center (Buffalo, N.Y.), St. Elizabeth Healthcare (Edgewood, Ky.), and Baptist Memorial Health Care (Memphis, Tenn.) and nearly 100 people who share the desire to end lung cancer—now.

November 19, 2022:

The Big Ten Cancer Research Consortium Foundation announces that Edward M. Greenfield, PhD, has been awarded the $100,000 Kenneth and Verna Mae Jessen Award.

Dr. Greenfield is a member of the tumor microenvironment and metastasis research program at the Indiana University Melvin and Bren Simon Comprehensive Cancer Center and professor of orthopaedic surgery at IU School of Medicine.  

September 24, 2022: 

Register now for the 2022 Big Ten CRC Summit held Saturday, November 19, 2022, in Columbus, Ohio.

We invite all senior/junior faculty and fellows involved in clinical oncology research, basic scientists involved in drug discovery and translational research, cancer center leadership and administration, community leaders and patient advocates to join us in Columbus at no cost for registration. Industry leaders and medical science liaisons are invited to the summit and to give pipeline presentations for a fee. Read More